Aquestive therapeutics, inc. (AQST)
Income statement / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Sep'17Jun'17
Revenues

8,765

16,419

12,418

11,129

12,643

16,824

13,267

13,928

23,411

-

-

Revenues

-

-

-

-

-

-

-

-

-

27,146

11,142

Costs and expenses:
The aggregate costs incurred in the production of goods and supply for sale.

3,659

6,792

4,643

5,420

3,506

4,787

5,592

4,973

5,636

4,880

5,141

Research and development

4,354

3,057

5,063

8,151

4,303

5,683

4,534

7,994

4,901

5,684

4,837

Selling, general and administrative

14,613

16,474

13,714

16,246

17,908

18,686

12,346

33,668

7,569

6,161

5,223

Total costs and expenses

22,626

26,323

23,420

29,817

25,717

29,156

22,472

46,635

18,106

16,725

15,201

Loss from operations

-13,861

-9,904

-11,002

-18,688

-13,074

-12,327

-9,205

-32,707

5,305

10,421

-4,059

Other income/(expenses):
Interest expense

2,771

2,803

2,652

1,937

1,926

1,924

1,933

1,927

1,927

1,970

1,949

Interest income

102

71

138

153

274

312

216

0

24

0

-

Loss on the extinguishment of debt

-

-

-4,896

-

-

-

0

-

-

-

-

Change in fair value of warrant

-

-

0

0

-

0

4,116

1,859

-697

0

-111

Other, net

-

-

-

-

-

-

-

-

-

0

0

Net loss before income taxes

-16,530

-12,636

-18,412

-20,472

-14,726

-13,944

-15,038

-36,493

4,099

8,451

-5,897

Income taxes

0

0

0

0

0

0

0

0

0

0

0

Net loss

-16,530

-12,636

-18,412

-20,472

-14,726

-13,944

-15,038

-36,493

4,099

8,451

-5,897

Dividends on redeemable preferred interests

-

-

-

-

-

-

-

-

-

626

615

Net loss attributable to common shares/ members' interests

-

-

-

-

-

-

-

-

-

7,825

-6,512

Comprehensive loss

-16,530

-12,636

-18,412

-20,472

-14,726

-13,944

-15,038

-36,493

4,099

7,825

-6,512

Net loss per share - basic and diluted (in dollars per share)

-0.49

-0.46

-0.74

-0.82

-0.59

-0.69

-0.64

-1.90

0.27

-

-

Weighted-average number of common shares outstanding - basic and diluted (in shares)

33,569

26,448

25,031

24,980

24,963

24,989

23,646

19,188

15,077

-

-